Eurofins Cerep SA provides various drug discovery services to pharmaceutical and biotechnology companies worldwide. More Details
Solid track record with excellent balance sheet.
Share Price & News
How has Eurofins-Cerep's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: Insufficient data to determine ALECR's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine ALECR's volatility change over the past year.
7 Day Return
FR Life Sciences
1 Year Return
FR Life Sciences
Return vs Industry: Insufficient data to determine how ALECR performed against the French Life Sciences industry.
Return vs Market: Insufficient data to determine how ALECR performed against the French Market.
Long-Term Price Volatility Vs. Market
How volatile is Eurofins-Cerep's share price compared to the market and industry in the last 5 years?
Simply Wall St News
11 months ago | Simply Wall StHow Does Eurofins-Cerep SA's (EPA:ALECR) Earnings Growth Stack Up Against Industry Performance?
2 years ago | Simply Wall StDoes Eurofins-Cerep's (EPA:ALECR) Share Price Gain of 33% Match Its Business Performance?
2 years ago | Simply Wall StHow Financially Strong Is Eurofins-Cerep SA (EPA:ALECR)?
Is Eurofins-Cerep undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Eurofins-Cerep is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Eurofins-Cerep has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
How is Eurofins-Cerep forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Eurofins-Cerep has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Eurofins-Cerep performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALECR has high quality earnings.
Growing Profit Margin: ALECR's current net profit margins (17.9%) are higher than last year (10.6%).
Past Earnings Growth Analysis
Earnings Trend: ALECR's earnings have grown significantly by 20.8% per year over the past 5 years.
Accelerating Growth: ALECR's earnings growth over the past year (109.8%) exceeds its 5-year average (20.8% per year).
Earnings vs Industry: ALECR earnings growth over the past year (109.8%) exceeded the Life Sciences industry 48.8%.
Return on Equity
High ROE: ALECR's Return on Equity (18.4%) is considered low.
How is Eurofins-Cerep's financial position?
Financial Position Analysis
Short Term Liabilities: ALECR's short term assets (€34.9M) exceed its short term liabilities (€7.6M).
Long Term Liabilities: ALECR's short term assets (€34.9M) exceed its long term liabilities (€2.5M).
Debt to Equity History and Analysis
Debt Level: ALECR's debt to equity ratio (0.01%) is considered satisfactory.
Reducing Debt: ALECR's debt to equity ratio has reduced from 0.6% to 0.01% over the past 5 years.
Debt Coverage: Insufficient data to determine if ALECR's debt is well covered by operating cash flow.
Interest Coverage: ALECR's interest payments on its debt are well covered by EBIT (127.6x coverage).
What is Eurofins-Cerep current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALECR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALECR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALECR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALECR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALECR's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Antoine Duthilleul has been Managing Director and Director at Eurofins Cerep SA since April 19, 2018. He has been President of The Eurofins Discovery Products France at Eurofins-Cerep SA since February 28,...
Experienced Board: ALECR's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Eurofins-Cerep SA's company bio, employee growth, exchange listings and data sources
- Name: Eurofins-Cerep SA
- Ticker: ALECR
- Exchange: ENXTPA
- Founded: 1989
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: €71.120m
- Shares outstanding: 5.04k
- Website: https://www.eurofins.fr/cerep
Number of Employees
- Eurofins-Cerep SA
- Le Bois l'Evêque
- Celle L'Evescault
Eurofins Cerep SA provides various drug discovery services to pharmaceutical and biotechnology companies worldwide. The company’s research services include compound management, high-throughput screening, i...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/16 19:22|
|End of Day Share Price||2021/04/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.